Literature DB >> 23737214

Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.

Eyup Sabri Ercan1, Ulku Akyol Ardic, Burge Kabukcu Basay, Elif Ercan, Omer Basay.   

Abstract

The DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 1994, American Psychiatric Association) describes attention deficit hyperactivity disorder (ADHD) as a heterogeneous disorder; providing diagnostic criteria for three subtypes: hyperactive/impulsive (ADHD/HI), inattentive (ADHD/I), and combined type (ADHD/C). Differences among the subtypes are well defined, but there may be also differences in terms of treatment responses. The aim of this study is to assess the responses of ADHD/I and ADHD/C to atomoxetine treatment. The medical records of the January-June 2012 term, first time referrals to outpatient clinic, were reviewed, and 37 ADHD diagnosed primary school age children (18 ADHD/I, 19 ADHD/C) that were treated with atomoxetine were determined. Thirty-five of them who completed 8 weeks of treatment duration were recruited for the study. The children with an ADHD medication use history in 2 months time prior to onset of treatment and/or the children receiving additional psychopharmacologic treatment to atomoxetine were excluded. Baseline and eighth week assessment, records were evaluated. Efficacy assessments included Turgay DSM-IV ADHD Screening and Rating Scale parent and teacher forms (T-DSM-IV) and Clinical Global Impression Scale-Severity and Improvement subscales. Safety assessments included laboratory and body weight assessments, ECG, heart rate, and blood pressure evaluations (baseline and eighth week) along a scale filled by the parents at the eighth week to review side effects. Atomoxetine was found to be effective in both ADHD/I and ADHD/C groups. Atomoxetine also decreased the opposition defiance subscale scores of T-DSM-IV (both parent and teacher forms), whereas it was not found to make statistically significant difference in the conduct disorder subscale scores. Mean difference in 8-week time in T-DSM-IV hyperactivity subscale and total scores of parent and teacher forms; inattention subscale scores of only parent forms and the CGI- severity subscale scores; differed significantly among the ADHD/I and ADHD/C groups; that ADHD/C types responded better to medication. Results of this study revealed that atomoxetine is effective both in ADHD/I and ADHD/C subtypes. ADHD/C types may be responding better to atomoxetine treatment than the ADHD/I subtypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23737214     DOI: 10.1007/s12402-013-0111-0

Source DB:  PubMed          Journal:  Atten Defic Hyperact Disord        ISSN: 1866-6116


  4 in total

Review 1.  The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.

Authors:  Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 2.  A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.

Authors:  David B Clemow; Chris Bushe; Michele Mancini; Michael H Ossipov; Himanshu Upadhyaya
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-03       Impact factor: 2.570

3.  Evaluation of Two Types of Drug Treatment with QEEG in Children with ADHD.

Authors:  Ramazan Aldemir; Esra Demirci; Ayşe Kaçar Bayram; Mehmet Canpolat; Sevgi Ozmen; Hüseyin Per; Mahmut Tokmakci
Journal:  Transl Neurosci       Date:  2018-09-01       Impact factor: 1.757

4.  Perpetration of and Victimization in Cyberbullying and Traditional Bullying in Adolescents with Attention-Deficit/Hyperactivity Disorder: Roles of Impulsivity, Frustration Intolerance, and Hostility.

Authors:  Tai-Ling Liu; Ray C Hsiao; Wen-Jiun Chou; Cheng-Fang Yen
Journal:  Int J Environ Res Public Health       Date:  2021-06-26       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.